Breaking News, Collaborations & Alliances

RevOpsis, Kemwell Enter Manufacturing Partnership to Accelerate Development of RO-104

Collaboration leverages Kemwell's manufacturing excellence and RevOpsis' Rev-Mod platform to expedite the development of novel multispecific biologics.

Author Image

By: Charlie Sternberg

Associate Editor

RevOpsis Therapeutics, a biopharmaceutical company spearheading innovation of multispecific ophthalmic therapies, and Kemwell Biopharma Pvt. Ltd., a biologics contract development and manufacturing organization (CDMO), have entered a broad strategic manufacturing partnership which aims to accelerate the development of RevOpsis’ lead candidate, RO-104, a first-in-class tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD).   Under this partnership,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters